Skip to content
ppharmaranks
Menu
Class IIOngoing

Metoprolol Succinate Extended-Release Tablets recall

FDA recall D-0356-2026 · initiated Jan 29, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Mar 11, 2026How we research

Teva Pharmaceuticals USA, Inc recalled Metoprolol Succinate Extended-Release Tablets in Jan 2026 — an FDA Class II recall (D-0356-2026) because Failed Dissolution Specifications.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Failed Dissolution Specifications

Wrong strength, or it did not keep

The product did not contain what the label promised, or stopped meeting specification before its expiry date. Under-strength medicine can mean an untreated condition.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot#: a) 0718J251, 0729J251, 0730J251, Exp.: 12/2026; b) 0718J252, 0729J252, 0730J252, Exp.: 12/2026.

Quantity recalled: 7,448 bottles

Details

Product
Metoprolol Succinate Extended-Release Tablets, Rx Only, 100 mg, 100 tablets bottles (NDC: 45963-677-11) and 1,000 tablets bottles (NDC: 45963-677-96), Teva Pharmaceuticals, Parsippany, NJ 07054.
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
Nationwide
Initiated
Jan 29, 2026
FDA report date
Mar 11, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Metoprolol Succinate Extended-Release Tablets recalled?
Teva Pharmaceuticals USA, Inc recalled Metoprolol Succinate Extended-Release Tablets in Jan 2026 — an FDA Class II recall (D-0356-2026) because Failed Dissolution Specifications. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Metoprolol Succinate Extended-Release Tablets recalled?
Per the FDA enforcement record, the reason for recall D-0356-2026 was: Failed Dissolution Specifications
Is a recalled Metoprolol Succinate Extended-Release Tablets dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Metoprolol Succinate Extended-Release Tablets are affected?
Distributed: Nationwide. The recall covers these lots — Lot#: a) 0718J251, 0729J251, 0730J251, Exp.: 12/2026; b) 0718J252, 0729J252, 0730J252, Exp.: 12/2026.. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0356-2026.

Source: openFDA Drug Enforcement record D-0356-2026

← All drug recalls